摘要
目的:探讨慢阻肺患者使用舒利迭与补中益气汤治疗的临床价值。方法:按照随机抽签法将2017年6月至2018年6月在新疆喀什地区第二人民医院诊治的86例重症FEV1≤预计值50%的慢阻肺患者分配入组,Ⅰ组(n=43)接受舒利迭单药治疗,Ⅱ组(n=43)在舒利迭用药基础上施加补中益气汤治疗,分析评估两组治疗对患者病情的改善情况。结果:Ⅱ组患者在临床疗效的优化方面较Ⅰ组明显,总有效率提高至97.7%,比较有统计学意义(P<0.05)。治疗前,两组在各项肺功能指标(FVC、FEV1/FVC等)与指脉氧饱和度上的对比,差异不具统计学意义(P>0.05);治疗后,Ⅱ组患者在各项肺功能指标(FVC、FEV1/FVC等)与指脉氧饱和度的改善方面较Ⅰ组更明显,结果有统计学意义(P<0.05)。实验期间,两组均未观察到有严重的药物副反应发生。结论:对慢阻肺患者使用舒利迭与补中益气汤共同治疗,临床疗效显著、安全,且可加速恢复患者的肺功能,值得推荐。
Objective: To investigate the clinical value of seretide and buzhongyiqi Decoction in the treatment of chronic obstructive pulmonary disease. Methods: A total of 86 COPD patients with severe FEV1 ≤ 50% of the predicted value were randomly divided into two groups. GroupⅠ (n = 43) was treated with seretide and group Ⅱ (n = 43) was treated with buzhongyiqi decoction on the basis of seretide.Patient situation was compared. Results: The clinical efficacy of group Ⅱ was better than that of group Ⅰ,and the total effective rate increased to 97.7%. The difference was statistically significant (P<0.05). Before treatment,there was no significant difference between the two groups in lung function indexes (FVC,FEV1/FVC,etc.) and finger oxygen saturation (P>0.05); after treatment,the improvement of lung function indexes (FVC,FEV1/FVC,etc.) and finger oxygen saturation in group Ⅱ was more obvious than that in group Ⅰ,and the results were statistically significant (P<0.05). During the experiment,no serious side effects were observed in the two groups. Conclusion: Seretide combined with buzhongyiqi decoction is effective and safe in treating COPD patients,and can accelerate the recovery of lung function,which is worthy of recommendation.
作者
王阿红
席玉镜
WANG A-Hong;XI Yu-Jing(The Second Peopled Hospital of Kashi District, Kashi 844000, China)
出处
《转化医学电子杂志》
2018年第10期47-49,共3页
E-Journal of Translational Medicine
关键词
慢阻肺
舒利迭
补中益气汤
临床价值
chronic obstructive pulmonary disease
seretide
buzhongyiqi decoction
clinical value
作者简介
王阿红。本科,主治医师。研究方向:呼吸病学。Tel:0998-2576072 E-mail:xiyUjing759@sina.com
